Sanofi drops plans to seek global approvals for amlitelimab in atopic dermatitis amid portfolio review

Sanofi will stop clinical development of amlitelimab in moderate-to-severe atopic dermatitis, dropping plans for global regulatory submissions.

The portfolio review will redirect resources, citing an unfavorable efficacy-safety balance and no meaningful improvement versus standard of care in atopic dermatitis.

Ongoing atopic dermatitis studies will be wound down with site and regulator coordination to support patient care transitions.

2026 financial guidance remains unchanged despite the atopic dermatitis program termination.

Development continues in celiac disease, with phase 2 results expected in the second half of 2026.